Mahatme Sandesh
SEC insider (Form 3/4/5 filer). CIK 0001511034. Director at CRISPR Therapeutics AG (CRSP) and 1 other issuer. 5 reported Form 4/5 transactions since Sep 2024; latest on Jun 5, 2026. Located in BOSTON, MA.
Companies Mahatme Sandesh has filed insider reports for
- CRISPR Therapeutics AG (CRSP): Director
- Vor Biopharma Inc. (VOR): Officer, CFO
Mahatme Sandesh
CIK: 0001511034
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- Jun 5, 2026CRSP
CRISPR Therapeutics AG
AwardDirectStock Option (Right to Buy)
13K shares- - Dec 5, 2025VOR
Vor Biopharma Inc.
DispositionDirect694.1K shares- - Dec 5, 2025VOR
Vor Biopharma Inc.
AwardDirectEmployee Stock Option (right to buy)
1.4M shares- - Jul 9, 2025VOR
Vor Biopharma Inc.
AwardDirect13.9M shares- - Jun 5, 2025CRSP
CRISPR Therapeutics AG
AwardDirectStock Option (Right to Buy)
13K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 5, 2026 |  CRSP CRISPR Therapeutics AG | Award Stock Option (Right to Buy) | 13,000 | - | - | Direct |
| Dec 5, 2025 |  VOR Vor Biopharma Inc. | Disposition | 694,137 | - | - | Direct |
| Dec 5, 2025 | VOR Vor Biopharma Inc. | Award Employee Stock Option (right to buy) | 1,388,274 | - | - | Direct |
| Jul 9, 2025 | VOR Vor Biopharma Inc. | Award | 13,882,750 | - | - | Direct |
| Jun 5, 2025 | CRSP CRISPR Therapeutics AG | Award Stock Option (Right to Buy) | 13,000 | - | - | Direct |
1-5 of 5 transactions